---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-017846"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:24:46.685843+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Anteris terminates v2v development deal, pays $400K break fee

## Summary
- Notified v2vmedtech of discontinuation of development contributions after Stage 1 completion.
- Break fee of $400,000 payable to v2v; no further contribution obligations.
- v2v shareholders may either buy back Anteris' equity at cost or reduce it to capped minority.
- Related Development Agreement will terminate upon break fee payment.
- Company expects no material adverse effect on consolidated financial position.

## SEC filing metadata
- accession: 0001140361-26-017846
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036126017846/0001140361-26-017846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036126017846/ef20071159_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-017846
- JSON: https://secwatch.observer/filing/0001140361-26-017846.json
- Plain text: https://secwatch.observer/filing/0001140361-26-017846.txt

## Source-grounded claims
- claim_id: d101b5cd3a3903344a0b4e1f0d80ad9058e0af7e
  claim: Anteris Technologies Global Corp. terminated Contribution and Stock Purchase Agreement with v2vmedtech, inc. valued at break fee of $400,000 (effective 2026-04-28).
  evidence_excerpt: On April 28 , 2026, Anteris Technologies Global Corp., through its wholly owned subsidiary, Anteris Technologies Corporation (the “Company”), notified v2vmedtech, inc. (“v2v”) of its election to discontinue additional development contributions under the Contribution and Stock Purchase Agreement dated April 18, 2023 (the “Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/2011514/000114036126017846/0001140361-26-017846-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.